HANALL BIOPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31,550 KRW | -14.50% |
|
-11.87% | -28.78% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,857,720 | 1,919,220 | 1,077,892 | 902,290 | 2,245,705 | 1,599,368 | - | - |
| Enterprise Value (EV) 2 | 1,763 | 1,829 | 998.7 | 859.7 | 2,190 | 1,521 | 1,540 | 1,515 |
| P/E ratio | 96.8 x | 97.2 x | 121 x | 3,560 x | 642 x | 770 x | 151 x | 84.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.1 x | 21.7 x | 10.6 x | 8.2 x | 16.6 x | 10.9 x | 9.41 x | 8.46 x |
| EV / Revenue | 16.3 x | 20.6 x | 9.83 x | 7.82 x | 16.2 x | 10.4 x | 9.07 x | 8.02 x |
| EV / EBITDA | 89 x | 207 x | 77.9 x | 189 x | 401 x | 254 x | 96 x | 63.1 x |
| EV / FCF | 86.9 x | -1,120 x | -265 x | 38.4 x | 80.4 x | 84.5 x | 60.7 x | 49.1 x |
| FCF Yield | 1.15% | -0.09% | -0.38% | 2.6% | 1.24% | 1.18% | 1.65% | 2.04% |
| Price to Book | 12.3 x | 12.7 x | 6.59 x | 5.38 x | 12.1 x | 8.65 x | 8.2 x | 6.76 x |
| Nbr of stocks (in thousands) | 51,177 | 51,179 | 51,206 | 50,690 | 50,693 | 50,693 | - | - |
| Reference price 3 | 36,300 | 37,500 | 21,050 | 17,800 | 44,300 | 31,550 | 31,550 | 31,550 |
| Announcement Date | 1/16/20 | 1/19/21 | 1/18/22 | 1/19/23 | 1/24/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 108.5 | 88.6 | 101.6 | 110 | 134.9 | 146.2 | 169.9 | 189 |
| EBITDA 1 | 19.8 | 8.829 | 12.82 | 4.558 | 5.458 | 6 | 16.04 | 24 |
| EBIT 1 | 17.09 | 5.935 | 10.1 | 1.506 | 2.211 | 2.8 | 12.42 | 20.67 |
| Operating Margin | 15.76% | 6.7% | 9.94% | 1.37% | 1.64% | 1.92% | 7.31% | 10.93% |
| Earnings before Tax (EBT) 1 | 17.46 | 19.57 | 8.702 | 1.929 | 3.203 | 3.25 | 14.06 | 23.33 |
| Net income 1 | 19.17 | 19.76 | 10 | 1.988 | 3.509 | 2.067 | 10.96 | 19.67 |
| Net margin | 17.68% | 22.31% | 9.84% | 1.81% | 2.6% | 1.41% | 6.45% | 10.41% |
| EPS 2 | 375.0 | 386.0 | 174.0 | 5.000 | 69.00 | 41.00 | 209.6 | 372.7 |
| Free Cash Flow 3 | 20,279 | -1,633 | -3,766 | 22,374 | 27,231 | 18,000 | 25,367 | 30,867 |
| FCF margin | 18,698.28% | -1,843.1% | -3,706.93% | 20,340.98% | 20,184.44% | 12,315.27% | 14,930.35% | 16,331.57% |
| FCF Conversion (EBITDA) | 102,393.28% | - | - | 490,829.07% | 498,886.92% | 300,000% | 158,146.3% | 128,611.11% |
| FCF Conversion (Net income) | 105,759.31% | - | - | 1,125,211.15% | 776,113.46% | 870,966.34% | 231,447.69% | 156,949.13% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 1/16/20 | 1/19/21 | 1/18/22 | 1/19/23 | 1/24/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.88 | 23.99 | 26.25 | 29.64 | 30.12 | 28.8 | 41.42 | 33 | 31.72 | 34.1 | 34.4 | 37.5 | 35.9 |
| EBITDA | - | - | - | - | - | - | 8.589 | 0.6727 | -3.403 | - | - | - | - |
| EBIT 1 | 0.9244 | -0.592 | 0.6815 | 0.6218 | 0.7943 | -1.738 | 7.997 | 0.1 | -4.264 | - | 0.4 | 1.4 | 1.8 |
| Operating Margin | 3.71% | -2.47% | 2.6% | 2.1% | 2.64% | -6.04% | 19.31% | 0.3% | -13.44% | - | 1.16% | 3.73% | 5.01% |
| Earnings before Tax (EBT) | 0.3048 | -0.0148 | 0.579 | 0.7344 | 0.6308 | - | 8.203 | 0.5108 | - | - | - | - | - |
| Net income 1 | -0.9503 | -0.083 | -0.0772 | 0.7344 | -0.3229 | -1.254 | 7.306 | 0.3 | -2.863 | -0.3 | 0.6 | 1.3 | 1.6 |
| Net margin | -3.82% | -0.35% | -0.29% | 2.48% | -1.07% | -4.35% | 17.64% | 0.91% | -9.03% | -0.88% | 1.74% | 3.47% | 4.46% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 1/18/22 | 4/28/22 | 8/16/22 | 11/29/22 | 1/19/23 | 5/15/23 | 7/26/23 | 10/26/23 | 1/24/24 | 4/30/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 94.9 | 90.2 | 79.2 | 42.6 | 55.2 | 78 | 58.9 | 84 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | 20,279 | -1,633 | -3,766 | 22,374 | 27,231 | 18,000 | 25,367 | 30,867 |
| ROE (net income / shareholders' equity) | 14.3% | 13.4% | 5.78% | 1.19% | 1.98% | 1.13% | 5.4% | 8.23% |
| ROA (Net income/ Total Assets) | 10.6% | 10.6% | 4.25% | 0.12% | 1.55% | 0.87% | 4.18% | 6.37% |
| Assets 1 | 180.9 | 187.1 | 235.3 | 1,629 | 226.6 | 238.5 | 262.2 | 308.9 |
| Book Value Per Share 3 | 2,946 | 2,946 | 3,193 | 3,311 | 3,674 | 3,649 | 3,849 | 4,667 |
| Cash Flow per Share 3 | 400.0 | 18.10 | - | - | 585.0 | 128.0 | 176.0 | 202.0 |
| Capex 1 | 2.12 | 2.56 | 4.61 | 2.83 | 2.41 | 3.13 | 3.33 | 1.5 |
| Capex / Sales | 1.96% | 2.89% | 4.53% | 2.57% | 1.79% | 2.14% | 1.96% | 0.79% |
| Announcement Date | 1/16/20 | 1/19/21 | 1/18/22 | 1/19/23 | 1/24/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31,550
KRW
Average target price
43,600
KRW
Spread / Average Target
+38.19%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.78% | 1.16B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- A009420 Stock
- Financials Hanall Biopharma Co., Ltd.
